Mielóma multiplex: vizsgálatok itt: Egyesült Királyság

In Egyesült Királyság 49 Also abroad 703

49 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

1. fázisTaking people
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
London, Manchester
Életkor
18 év and over
People
250 worldwide
Run by
AbbVie
See details and how to joinNCT05650632 · EU 2023-504674-38-00
3. fázisTaking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
London, Oxford, Wolverhampton
Életkor
18 év and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
3. fázisTaking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Birmingham, Cambridge, Edinburgh, London, Manchester
Életkor
18 év and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
3. fázisTaking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Aberdeen, Birmingham, Dundee, Manchester, Norwich, Plymouth, Sutton, Truro
Életkor
18 év and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
3. fázisTaking people
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Where
Leicester, London, Norwich, Sutton, Truro
Életkor
18 év and over
People
270 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00
3. fázisTaking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
Életkor
18 év and over
People
1590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
1. fázisTaking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
London, Sutton
Életkor
18 év and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
3. fázisTaking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
Életkor
18 év and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
3. fázisTaking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Colchester, Edinburgh, Heath Town, London
Életkor
18 év and over
People
1000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
3. fázisTaking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Airdrie, Barnet, Cambridge, Leicester, London, Newcastle upon Tyne, Stoke-on-Trent, Truro
Életkor
18 év and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
1/2. fázisTaking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Leeds, Manchester, Plymouth
Életkor
18 év and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
2. fázisTaking people
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Where
Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Sutton, Windsor
Életkor
18 év and over
People
100 worldwide
Run by
C4 Therapeutics, Inc.
See details and how to joinNCT07284758 · EU 2025-524181-26-00
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Cambridge, London, Manchester, Newcastle upon Tyne, Oxford, Sheffield
Életkor
18 év and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
3. fázisTaking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Birmingham, Cardiff, Edinburgh, Glasgow, Leicester, London, Oxford, Reading, Stoke-on-Trent
Életkor
18 év and over
People
1060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
1/2. fázisTaking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Manchester, Oxford
Életkor
18 év and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
1/2. fázisTaking people
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Where
Sutton
Életkor
18 év and over
People
387 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00
1/2. fázisTaking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Headington, London, Sutton
Életkor
18 év and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
3. fázisTaking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Cambridge, London
Életkor
18 év to 130 év
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
1. fázisTaking people
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
London, Sutton
Életkor
18 év and over
People
186 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00
2. fázisTaking people
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Where
Aberdeen, Birmingham, Bristol, Cardiff, Derby, Leeds, London, Nottingham, Nuneaton, Oxford, Wales
Életkor
18 év and over
People
63
Run by
University College, London
See details and how to joinNCT06762769
1/2. fázisTaking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Where
Birmingham, Cardiff, London
Életkor
18 év to 64 év
People
602 worldwide
Run by
AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00
3. fázisTaking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Leicester, London
Életkor
18 év and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
3. fázisTaking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Cardiff, Colcester, Exeter, Gloucester, Milton Keynes, Stafford
Életkor
18 év and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
3. fázisTaking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Birmingham, Bristol, Glasgow, Scotland, London
Életkor
18 év and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
2. fázisTaking people
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Where
Belfast, Colchester, Eastbourne, Liverpool, London, Manchester, Newcastle upon Tyne
Életkor
18 év and over
People
210 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00